Micrus Corp.
Executive Summary
Micrus hopes to break into the underpenetrated market of minimally invasive treatments for cerebral aneurysms with a microcoil that has, it claims, performance characteristics that are superior to Target Therapeutics' Guglielmi Detachable Coil.
You may also be interested in...
Shades of BENESTENT in the Aneurysm World
UK investigators' recent decision to call an early halt to enrollment in a major study comparing neurosurgical clipping to endovascular coil treatment of ruptured cerebral aneurysms may signal a significant change of practice habits in a critical area of neurology. The findings, if they're as good as they appear to be, could do to surgical clipping and endovascular coils what the BENESTENT trials of the early 1990s did to promote stenting over balloon angioplasty in patients with coronary artery disease.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”